thehealthequity.com
DEA approves synthetic marijuana for big pharma company against legalization | The Health Equity
A synthetic marijuana product could be available for commercialization after the DEA gave a newly approved drug a schedule II classification. On Thursday, Insys Therapeutics announced that the Drug Enforcement Administration (DEA) issued an interim final rule that would put Syndros, their synthetic marijuana drug, on Schedule II of the Controlled Substances Act (CSA).